Diagnosing Dx – Détails, épisodes et analyse

Détails du podcast

Informations techniques et générales issues du flux RSS du podcast.

Diagnosing Dx

Elevra Consulting

Sciences

Fréquence : 1 épisode/95j. Total Éps: 55

How do we transform cutting-edge scientific discoveries into life-saving diagnostics? On Diagnosing Dx, we explore the scientific innovation driving diagnostics forward, unpack industry challenges, and spotlight success stories. Join us as we speak with leading researchers and innovators at the forefront of Dx. Learn to: 🔹 Navigate industry challenges 🔹 Understand emerging science 🔹 Strategise for growth 🔹 Gain future-focused insight Essential listening for everyone involved in bringing new sciences to life in the Dx and Omics industry, Subscribe now!

Lire plusRéduire

Site

RSS

Apple

Données mises à jour le 11/09/2026

Classements récents

Dernières positions dans les classements Apple Podcasts et Spotify.

Apple Podcasts

🇨🇦 Canada - lifeSciences
11/09/2026
#50
🇬🇧 Grande Bretagne - lifeSciences
11/09/2026
#71
🇬🇧 Grande Bretagne - lifeSciences
10/09/2026
#55
🇬🇧 Grande Bretagne - lifeSciences
09/09/2026
#35
🇬🇧 Grande Bretagne - lifeSciences
18/08/2026
#99
🇬🇧 Grande Bretagne - lifeSciences
17/08/2026
#86
🇬🇧 Grande Bretagne - lifeSciences
16/08/2026
#71
🇬🇧 Grande Bretagne - lifeSciences
15/08/2026
#62
🇬🇧 Grande Bretagne - lifeSciences
14/08/2026
#46
🇬🇧 Grande Bretagne - lifeSciences
13/08/2026
#34

Spotify

Aucun classement récent disponible

Liens partagés entre épisodes et podcasts

Liens présents dans les descriptions d'épisodes et autres podcasts les utilisant également.

https://www.linkedin.com/in/davidfilby/
32 partages
https://www.linkedin.com/in/arnonchait/
2 partages
https://www.linkedin.com/in/nicoledaniellebell/
2 partages

https://elevraconsulting.com/
6 partages
https://canatu.com/products/medical-diagnostics/
2 partages
https://www.anywhere.health/
2 partages

https://kariusdx.com/
3 partages
https://www.galaxydx.com/
2 partages

Qualité et score du flux RSS

Évaluation technique de la qualité et de la structure du flux RSS.

Qualité du flux RSS

À améliorer

Score global : 48%

Historique des publications

Répartition mensuelle des publications d'épisodes au fil des années.

Year

Derniers épisodes publiés

Liste des épisodes récents, avec titres, durées et descriptions.

Could More Frequent Blood Testing Transform How We Detect Disease?

mercredi 9 septembre 2026 • Durée 39:43

In this episode of Diagnosing Dx, David Filby is joined by Octavian Florescu, CEO of In Diagnostics.

An electrical engineer and microchip designer by training, Octavian has spent his career exploring how semiconductor technology can be applied to blood testing. After building and exiting his first diagnostics company, he took those lessons into In Diagnostics alongside his co-founder and wife, Ana.

Octavian explains how the company is developing microchip-based blood testing from a drop of blood, why they are launching first in the veterinary market, and how a two-person “minimum viable company” is working towards profitability before expanding further into human diagnostics.

We also discuss what founders learn when capital is scarce, why diagnostics may need different funding models, and how better access to longitudinal blood data could support more personalised healthcare.

Key takeaways:
🔹 Why Octavian believes blood testing should become more frequent and accessible
🔹 How lessons from his first diagnostics company shaped In Diagnostics
🔹 Why the veterinary market offers an early route to revenue and product validation
🔹 The thinking behind building a two-person “minimum viable company”
🔹 Why diagnostics funding may need to move beyond traditional venture timelines

Chapters:
01:02 Introduction and Octavian Florescu’s background
04:32 From microchip design to blood testing
06:33 Lessons from his first diagnostics company
11:20 Building In Diagnostics as a minimum viable company
13:52 Microchip-based blood testing and the unmet need for more data
19:15 Launching first in veterinary diagnostics
22:27 Building towards profitability without traditional VC funding
29:53 Upcoming milestones and the future of diagnostics

Guest: Octavian Florescu
CEO, In Diagnostics
LinkedIn: https://www.linkedin.com/in/octavian-florescu-51b28817/

Host: David Filby
Founder and CEO of Elevra Consulting
LinkedIn: https://www.linkedin.com/in/davidfilby/

🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.

Lire plusRéduire

Why Are Vector-Borne Infections Still So Difficult to Diagnose?

mercredi 2 septembre 2026 • Durée 36:15

In this episode of Diagnosing Dx, David Filby is joined by Nicole Bell, CEO of Galaxy Diagnostics.

Nicole’s route into vector-borne disease diagnostics is deeply personal. After her husband was initially diagnosed with early-onset Alzheimer’s disease, she continued searching for answers and later discovered he had Lyme disease alongside Babesia and Bartonella infections.

That experience led Nicole to Galaxy Diagnostics, where the company is working to improve direct detection of vector-borne infections using approaches including urine antigen testing and high-sensitivity PCR.

Nicole discusses why these infections are so difficult to diagnose, how outdated and antibody-based testing can leave patients without clear answers, and Galaxy’s plans to take its Lyme urine antigen test through clinical studies towards FDA submission.

Key takeaways:
🔹 Why Lyme, Bartonella and Babesia can be particularly difficult to detect
🔹 The limitations of relying on antibody testing for active infection
🔹 Why vector-borne disease exposure extends far beyond obvious tick bites
🔹 How Galaxy Diagnostics is approaching direct pathogen detection
🔹 The company’s path towards FDA approval, reimbursement and broader adoption

Chapters:
00:57 Introduction and Nicole Bell’s background
02:43 The personal story behind Nicole’s move into vector-borne diagnostics
08:17 Why vector-borne infections are so difficult to diagnose
13:28 Galaxy Diagnostics and its direct detection approach
17:22 How widespread is the vector-borne disease problem?
22:05 Commercialisation, clinical studies and the path to FDA approval
27:13 Raising a Series A in a difficult diagnostics market
31:31 Upcoming milestones and the future of diagnostics

Guest: Nicole BellCEO, Galaxy DiagnosticsLinkedIn:

What Can Diagnostics Founders Learn From Two Successful Exits? Andrew Miller

mercredi 26 août 2026 • Durée 36:17

In this episode of Diagnosing Dx, David Filby is joined by Andrew Miller, a diagnostics founder, advisor and two-time exited CEO.

A scientist by training, Andrew founded and led companies focused on rapid molecular diagnostics, taking Ionian Technologies through acquisition by Alere and later building NAT Diagnostics, which was acquired by Becton Dickinson in 2020. The technology developed at Ionian ultimately became central to Abbott’s ID NOW platform.

Andrew shares what he learned from going through the acquisition process twice, why his second company was designed for sale from the outset, and the four risks he believes every diagnostics founder needs to manage: technology, operations, finance and commercial relevance.

Key takeaways:
🔹 What Andrew learned from two successful diagnostics exits
🔹 Why Ionian chose acquisition rather than funding the full journey to FDA approval
🔹 How the lessons from his first exit shaped NAT Diagnostics from day one
🔹 Why founders need to prepare for due diligence long before an acquisition process begins
🔹 The four risks Andrew uses to assess early-stage diagnostics companies

Chapters:
00:00 Introduction and Andrew Miller’s background
02:23 Two diagnostics exits and the opportunity in rapid molecular testing
04:03 Building Ionian Technologies
08:37 Why Ionian pursued an acquisition
15:00 Building NAT Diagnostics differently the second time
19:04 Designing a diagnostics company for acquisition
27:03 Advising founders and the four risks every startup faces
31:33 Where diagnostics is heading next

Guest: Andrew Miller, PhD
Diagnostics Founder, Advisor & Two-Time Exited CEO
LinkedIn: https://www.linkedin.com/in/andrew-miller-2670811/

98% of Cancer Patients Outside the US Miss Genomic Testing. Can AI Change That?

mardi 18 août 2026 • Durée 38:54

In this episode of Diagnosing Dx, David Filby is joined by Travis Wold, Chief Executive Officer at Imagenomix.

Travis brings experience across cancer diagnostics, genomics, liquid biopsy, and international commercialization. We explore how Imagenomix is using AI to help make genomic testing more accessible to cancer patients globally.

With around 98% of cancer patients outside the US not receiving NGS testing, Travis explains how analysing standard H&E pathology images could help identify patients who are more likely to benefit from confirmatory genomic testing.

We also discuss Imagenomix’s commercial strategy, digital pathology partnerships, and the longer-term potential for AI to support more precise treatment decisions in oncology.

Key takeaways:
🔹 Why access to genomic testing remains extremely limited outside the US
🔹 How Imagenomix uses AI to identify mutation signals from standard H&E pathology images
🔹 Why AI screening could reduce the cost and volume of unnecessary NGS testing
🔹 How digital pathology partnerships could help Imagenomix scale globally
🔹 Why predicting treatment response could become the next major step for AI in precision oncology

Chapters:
00:59 Introduction and Travis Wold’s background
05:29 From cancer diagnostics to the global genomic testing problem
09:42 The limitations of NGS and where AI fits into the workflow
13:36 Imagenomix’s mission and the 98% genomic testing gap
17:42 Funding, digital pathology partnerships, and commercial traction
20:36 Regulatory strategy, screening, and the path towards companion diagnostics
23:13 Can AI predict which cancer patients will respond to treatment?
32:56 Scaling Imagenomix globally and the milestones ahead

Could 20-Minute Hormone Testing Transform Patient Care? Nedal Safwat, SVP at Canatu

mardi 11 août 2026 • Durée 45:30

In this episode of Diagnosing Dx, David Filby is joined by Nedal Safwat, Senior Vice President of Medical Diagnostics at Canatu and President of Canatu Inc.

With more than 20 years in diagnostics, Nedal has held leadership roles across Cepheid, QIAGEN, bioMérieux and Luminex. He now leads Canatu’s expansion into medical diagnostics, taking the company’s carbon nanotube technology into point-of-care testing.

Nedal explains why Canatu has chosen hormone testing and sepsis as its first areas of focus, and why the company started with the unmet clinical need rather than trying to find an application for its technology.

We also discuss the opportunity for faster hormone testing, the shift towards decentralised diagnostics, reimbursement and design-to-cost, and how Canatu is combining the speed of a startup with the infrastructure and backing of an established company.

Key takeaways:
🔹 Why Canatu is bringing carbon nanotube technology into medical diagnostics
🔹 Why hormone testing and sepsis were selected as the company’s first focus areas
🔹 Why diagnostics companies should start with the unmet need and work backwards
🔹 How point-of-care hormone testing could improve convenience and reduce patient drop-off
🔹 Why reimbursement, cost and customer validation need to be considered from the beginning

Chapters:
00:53 Introduction and Nedal Safwat’s background
07:18 Canatu and the move into medical diagnostics
13:02 Why hormone testing and sepsis?
17:26 Starting with the unmet need and product-market fit
21:29 Partnerships, personalised hormone testing and patient demand
27:52 Product development and the path to commercialisation
32:57 Reimbursement, design-to-cost and startup culture
40:30 Future milestones and the diagnostics market outlook

Could a $127M Seed Round Change Women's Health Forever? - Dean Remy, Co-Founder @ Mativa Dx

mardi 4 août 2026 • Durée 38:25

In this episode of Diagnosing Dx, David Filby is joined by Dean Remy, Co-Founder and Chief Commercial Officer at Mativa Diagnostics.

Dean brings 35 years of experience across diagnostics, biotechnology, and therapeutics. He explains why pregnancy testing has barely changed in 50 years and how the traditional positive-or-negative result can leave women without critical information during the earliest weeks of pregnancy.

Mativa is developing a reusable handheld device combining multiplex biomarker testing, graphene nanosensor technology, an AI-enabled app, and immediate care navigation. The company is also building a large longitudinal maternal biorepository to support future diagnostics, biomarker discovery, and therapeutic development.

This is a practical conversation about maternal health innovation, consumer access, partnerships, regulation, data, and building a platform designed to support women throughout the pregnancy journey.

Key takeaways:
🔹 Why the traditional pregnancy test does not provide women with enough early information
🔹 How Mativa plans to identify risks such as ectopic pregnancy and pre-eclampsia
🔹 Why a longitudinal maternal biorepository could transform diagnostics and therapeutic development
🔹 How retail, healthcare, pharmaceutical, and diagnostic partnerships could accelerate adoption
🔹 Why supporting the complete patient journey could define the next generation of diagnostics

Chapters:
01:08 Introduction and Dean Remy’s background
03:24 Why maternal health urgently needs innovation
06:28 Mativa’s approach and the technology behind the platform
11:42 Building a comprehensive maternal biorepository
14:24 Commercial strategy and market positioning
17:13 Regulatory and reimbursement pathways
20:18 Capital raising and strategic partnerships25:34 The future of Mativa and maternal diagnostics

Red Drop’s Bet on Pain-Free Blood Collection and the Next Wave of Diagnostics

mardi 28 juillet 2026 • Durée 38:10

In this episode of Diagnosing Dx, David Filby is joined by Thomas Briggs, Chief Growth Officer at RedDrop Dx.

Thomas brings more than 25 years of diagnostics and healthcare growth experience, spanning pharma, big diagnostics, medtech, and startup environments. In this conversation, we explore one of the most overlooked parts of diagnostics: blood collection, and why the process still looks far too similar to what it did decades ago.

Thomas breaks down where arm-based micro-sampling could genuinely change patient experience, from paediatrics and neurodivergent patients to home testing, clinical trials, and difficult vein access.

We also get into the commercial reality behind a product like this: where the most promising markets are, why education still matters, how labs and platforms need to adapt, and what it takes to build a medtech business without following the usual VC-heavy playbook.

This is a practical conversation about workflow, access, patient experience, and what happens when a simple shift in blood collection could unlock broader changes across diagnostics and healthcare delivery.

Key takeaways:
🔹 Why blood collection remains one of the least-innovated parts of diagnostics
🔹 Where arm-based micro-sampling could have the biggest clinical and commercial impact
🔹 Why paediatrics, neurodivergent patients, and difficult vein access are such important use cases
🔹 How home sampling could change clinical trials, routine monitoring, and direct-to-consumer care
🔹 What it takes to commercialise a medtech product in both consumer and managed-care settings

Chapters:
01:51 Thomas Briggs’ background in diagnostics, pharma, and medtech
06:28 Moving from big corporates into startups
11:04 What RedDrop Dx is building and how the device works
14:39 Where the biggest commercial opportunities are for arm-based micro-sampling
18:48 Why education and awareness are still a major challenge
21:22 RedDrop Dx’s story so far and why it was bootstrapped
26:05 How the company is building for growth across different market segments
30:10 Future milestones, home collection clearance, and expansion into Europe31:31 Thomas’s outlook on diagnostics, home testing, and micro-sampling in 2026Guest: Thomas BriggsChief Growth Officer at RedDrop DxLinkedIn: Host: David FilbyFounder and CEO of Elevra ConsultingLinkedIn: 🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.

Why Cancer Patients Still Die From Infections We Can't Diagnose - Karius

mardi 21 juillet 2026 • Durée 51:23

In this episode of Diagnosing Dx, David Filby is joined by Alec Ford, Chief Executive Officer at Karius.

Alec brings decades of leadership experience across therapeutics, vaccines, and genomics. In this conversation, we explore how Karius is bringing genomics into infectious disease and why the company has focused so sharply on immunocompromised patients.

The scale of the unmet need is staggering. Alec explains that 52% of cancer deaths in the US are due to infection rather than the underlying malignancy, rising to more than 60% in hematologic malignancies. He also shares that there are around 4 million hospital admissions for infection among cancer patients in the US each year, yet the standard hospital workup can still fail to identify the cause in far too many cases.

We also discuss the company’s growth, physician adoption, and why outpatient infectious disease testing could become a major next step.

This is a practical conversation about infectious disease diagnostics, commercialization, and building in one of the most important unmet areas in healthcare.

Key takeaways:

🔹 Why infectious disease remains one of the biggest threats to immunocompromised patients
🔹 How Karius is using microbial cell-free DNA to diagnose infection from a simple blood draw
🔹 Why focus and disciplined market selection have been central to Karius’ growth
🔹 How physician confidence and education shape adoption of new diagnostics
🔹 Why outpatient infectious disease testing could become a major next step for the field

Chapters:
01:00 Introduction and Alec Ford’s background
04:20 Transition from therapeutics to genomics
08:34 The founding story of Karius and how the technology works14:52 Why Karius focused on immunocompromised patients19:41 Scaling the company and driving adoption27:20 Reimbursement, capital strategy, and path to profitability34:40 The outpatient opportunity and Karius’ next chapter45:03 Alec’s view on the diagnostics industry and what needs to change

Can AI Rescue Cancer Drugs That Clinical Trials Say Have Failed?

mercredi 15 juillet 2026 • Durée 36:28

In this episode of Diagnosing Dx, David Filby is joined by Alexander Bagaev, Chief Product Officer at BostonGene.

Alexander has spent more than a decade helping build BostonGene from an early-stage team into a global precision medicine company. In this conversation, we explore why oncology is moving beyond single biomarkers and how BostonGene has expanded from diagnostics into AI-powered treatment selection and clinical trial support.

We also discuss the challenge of bringing more comprehensive diagnostics into routine use, the role of multimodal data in better decision-making, and how BostonGene is working with pharma to design smarter trials from the outset.

This is a practical conversation about precision oncology, multimodal diagnostics, AI in drug development, and turning complex biology into clinically useful decisions.

Key takeaways:

🔹 Why single-gene and narrow-panel testing often misses the full picture in oncology
🔹 How BostonGene is combining genomics, transcriptomics, and immune profiling to improve treatment selection
🔹 Why reimbursement still lags behind the scientific need for integrated diagnostics
🔹 How multimodal AI and foundation models could reshape drug development and clinical trial design
🔹 What precision medicine companies need to understand about flexibility, regulation, and real-world adoption

Chapters:
00:00 Introduction to Alexander Bagaev
03:25 Journey from physics to immunology
05:07 The evolution of BostonGene
07:55 Precision medicine and patient-centric treatment selection
10:28 Challenges in drug development and clinical trials
13:02 Growth and milestones of BostonGene
15:19 Navigating diagnostics and the role of AI
20:48 Future opportunities and advice for early-stage companies

What If We Could Test Depression Drugs Before Patients Take Them? Dr Talia Cohen Solal - NeuroKaire

mardi 7 juillet 2026 • Durée 29:19

In this episode of Diagnosing Dx, David Filby is joined by Talia Cohen Solal, CEO at NeuroKaire.

Talia is a neuroscientist by training who spent more than a decade in academia, including time at Oxford, UCL, and Columbia, before moving into the startup world to get closer to real patient impact. In this conversation, we explore why precision medicine has transformed fields like oncology but still has so far to go in psychiatry, and how NeuroKaire is trying to change that.

We discuss the limits of current antidepressant prescribing and how NeuroKaire is using patient-derived neurons to predict which treatments are most likely to work for each individual.

This is a practical conversation about precision psychiatry, commercialization, clinical evidence, and what it takes to bring better mental health diagnostics into real patient care.

Key takeaways:

🔹 Why psychiatry still lacks the precision medicine approach seen in other fields
🔹 How NeuroKaire is using patient-derived neurons to guide antidepressant treatment
🔹 Why clinical trials and guideline change are essential for real adoption
🔹 How the company is balancing commercial growth with platform expansion and pharma partnerships
🔹 What the future could look like for diagnostics in depression, anxiety, ADHD, and beyond

Guest: Talia Cohen Solal
CEO at NeuroKaire

LinkedIn: https://www.linkedin.com/in/talia-cohen-solal-5b49a78/

Podcasts Similaires Basées sur le Contenu

Découvrez des podcasts liées à Diagnosing Dx. Explorez des podcasts avec des thèmes, sujets, et formats similaires. Ces similarités sont calculées grâce à des données tangibles, pas d'extrapolations !